| MeSH term | MeSH ID | Detail |
|---|---|---|
| Peri-Implantitis | D057873 | 1 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Peripheral Arterial Disease | D058729 | 7 associated lipids |
| Osteoporotic Fractures | D058866 | 1 associated lipids |
| Bisphosphonate-Associated Osteonecrosis of the Jaw | D059266 | 1 associated lipids |
| Angina, Stable | D060050 | 2 associated lipids |
| Vascular Calcification | D061205 | 1 associated lipids |
| Atrial Remodeling | D064752 | 1 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Naylor KE et al. | Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. | 2003 | J. Clin. Endocrinol. Metab. | pmid:14602774 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Terpos E et al. | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. | 2003 | Int. J. Cancer | pmid:12845688 |
| Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
| Wagner TU et al. | The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. | 2003 | Adv Space Res | pmid:15000082 |
| Novack DV | TSH, the bone suppressing hormone. | 2003 | Cell | pmid:14567908 |
| Abe E et al. | TSH is a negative regulator of skeletal remodeling. | 2003 | Cell | pmid:14567913 |
| Zhao ZM et al. | [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. | 2003 | Zhonghua Xue Ye Xue Za Zhi | pmid:14575594 |
| Han W et al. | Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. | 2003 | Biotechnol. Appl. Biochem. | pmid:12630898 |
| Koshihara Y et al. | Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. | 2003 | J. Endocrinol. | pmid:12630919 |
| Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
| Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
| Yonou H et al. | Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2003 | Cancer Res. | pmid:12727825 |
| Capparelli C et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | 2003 | J. Bone Miner. Res. | pmid:12733724 |
| Siggelkow H et al. | Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. | 2003 | J. Bone Miner. Res. | pmid:12619938 |
| Takayanagi H | [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. | 2003 | Seikagaku | pmid:14748148 |
| Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |
| Bridgham JT and Johnson AL | Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12878204 |
| Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
| Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
| Smith BB et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | 2003 Sep-Oct | Int. J. Toxicol. | pmid:14555415 |
| Ogasawara T et al. | In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. | 2004 | J. Periodont. Res. | pmid:14687227 |
| Blair HC and Athanasou NA | Recent advances in osteoclast biology and pathological bone resorption. | 2004 | Histol. Histopathol. | pmid:14702187 |
| Crotti TN et al. | Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. | 2004 | Biomaterials | pmid:14607494 |
| Vegni FE et al. | Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. | 2004 | N. Engl. J. Med. | pmid:14711922 |
| Crisafulli A et al. | Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. | 2004 | J. Clin. Endocrinol. Metab. | pmid:14715848 |
| Onyia JE et al. | Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. | 2004 | J. Pharmacol. Exp. Ther. | pmid:14718597 |
| Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
| Boabaid F et al. | Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. | 2004 | J. Periodontol. | pmid:15455742 |
| Kubota A et al. | Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. | 2004 | J. Rheumatol. | pmid:14994384 |
| Kötter I and Stübiger N | Therapeutic implications for interferon-alpha in arthritis. | 2004 | J. Rheumatol. | pmid:14994421 |
| Schett G et al. | Soluble RANKL and risk of nontraumatic fracture. | 2004 | JAMA | pmid:14996780 |
| Tsuji K et al. | Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. | 2004 | J. Bone Miner. Metab. | pmid:14999519 |
| Jørgensen HL et al. | Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. | 2004 | J. Bone Miner. Metab. | pmid:14999524 |
| Kobayashi-Sakamoto M et al. | NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15013432 |
| MacQuarrie RA et al. | Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. | 2004 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15015218 |
| Ishii T et al. | Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15033472 |
| Suda T and Miyaura C | [Recent advance in basic research for osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035090 |
| Matsumoto T | [Recent advances in the regulation of bone remodeling]. | 2004 | Nippon Rinsho | pmid:15035093 |
| Okumura S et al. | [Regulatory mechanism of osteoclast differentiation and function]. | 2004 | Nippon Rinsho | pmid:15035103 |
| Baek KH et al. | Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15001618 |
| Brage M et al. | Osteoclastogenesis is decreased by cysteine proteinase inhibitors. | 2004 | Bone | pmid:15003789 |
| Fukunaga J et al. | Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. | 2004 | Bone | pmid:15003790 |
| Sattler AM et al. | Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. | 2004 | Calcif. Tissue Int. | pmid:14523602 |
| Bergh JJ et al. | Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. | 2004 | Endocrinology | pmid:14525906 |
| Skoumal M et al. | Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. | 2004 | Ann. Rheum. Dis. | pmid:14722219 |
| WÅ‚odarski KH et al. | Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone. | 2004 | Folia Biol. (Krakow) | pmid:19058561 |
| Fan X et al. | Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. | 2004 | Endocrinology | pmid:14563699 |
| Yang KC et al. | [Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16114553 |
| Vanderborght A et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. | 2004 | J. Rheumatol. | pmid:15290725 |
| Soufi M et al. | Osteoprotegerin gene polymorphisms in men with coronary artery disease. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292302 |
| Schoppet M et al. | Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292354 |
| Lossdörfer S et al. | Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. | 2004 | J Biomed Mater Res A | pmid:15293309 |
| Kondo T et al. | 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. | 2004 | J. Bone Miner. Res. | pmid:15312241 |
| Daroszewska A et al. | Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. | 2004 | J. Bone Miner. Res. | pmid:15312251 |
| Liu JM et al. | [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. | 2004 | Zhonghua Nei Ke Za Zhi | pmid:15312444 |
| Jacobson A et al. | Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15313187 |
| Ishida M and Amano S | Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. | 2004 | J. Bone Miner. Metab. | pmid:15316862 |
| Sato T et al. | Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. | 2004 | Am. J. Hematol. | pmid:15307108 |
| Giuliani N et al. | New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). | 2004 | Exp. Hematol. | pmid:15308315 |
| Colucci S et al. | T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. | 2004 | Blood | pmid:15308561 |
| Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
| Kostenuik PJ | Revisiting the seed and soil theory of bone metastasis: new tools, same answer. | 2004 | J Musculoskelet Neuronal Interact | pmid:15758267 |
| Tsangari H et al. | Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. | 2004 | Bone | pmid:15207775 |
| Garlet GP et al. | Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. | 2004 | J. Clin. Periodontol. | pmid:15257746 |
| Baumann B et al. | Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. | 2004 | Acta Orthop Scand | pmid:15260421 |
| Tomek S et al. | Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. | 2004 | Gynecol. Oncol. | pmid:15262127 |
| Bord S et al. | Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. | 2004 | Br. J. Haematol. | pmid:15238146 |
| Buxton EC et al. | Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). | 2004 | J. Clin. Endocrinol. Metab. | pmid:15240611 |
| Kochanowska I et al. | Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. | 2004 | Cell Tissue Bank | pmid:15241009 |
| Corso A et al. | Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. | 2004 | Leukemia | pmid:15241438 |
| Harada M et al. | Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. | 2004 | Hum. Reprod. | pmid:15242994 |
| Kang HS et al. | Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. | 2004 | Mol. Cells | pmid:15232218 |
| Kazama JJ | Osteoprotegerin and bone mineral metabolism in renal failure. | 2004 | Curr. Opin. Nephrol. Hypertens. | pmid:15199291 |
| Walsh NC and Gravallese EM | Bone loss in inflammatory arthritis: mechanisms and treatment strategies. | 2004 | Curr Opin Rheumatol | pmid:15201606 |
| Terpos E et al. | Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. | 2004 | Leukemia | pmid:15215875 |
| Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
| Bengtsson AK et al. | 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. | 2004 | Blood | pmid:15142882 |
| Golledge J et al. | Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. | 2004 | Stroke | pmid:15143295 |
| Seshasayee D et al. | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. | 2004 | J. Biol. Chem. | pmid:15145935 |
| Yeung RS | The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. | 2004 | J. Rheumatol. | pmid:15124240 |
| Masi L et al. | Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? | 2004 | J. Rheumatol. | pmid:15124262 |
| Nitta K et al. | Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. | 2004 | Nephrol. Dial. Transplant. | pmid:15128884 |
| Milstead JR et al. | Spaceflight and hindlimb suspension disuse models in mice. | 2004 | Biomed Sci Instrum | pmid:15133943 |
| Karst M et al. | Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. | 2004 | J. Cell. Physiol. | pmid:15137062 |
| Su X et al. | [Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16137047 |
| Emanuele E et al. | Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. | 2004 | Int. J. Mol. Med. | pmid:15138623 |
| Kyrtsonis MC et al. | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. | 2004 | Eur. J. Haematol. | pmid:15089762 |
| Miao D et al. | Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. | 2004 | Endocrinology | pmid:15090463 |
| Haynes DR et al. | Regulation of osteoclast activity in peri-implant tissues. | 2004 | Biomaterials | pmid:15109848 |
| Clohisy DR and Mantyh PW | Bone cancer pain and the role of RANKL/OPG. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615497 |
| Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
| Jono S | [Risk factors of atherosclerosis in end-stage renal disease patients]. | 2004 | Clin Calcium | pmid:15576949 |
| Shimizu M and Tamura T | [Regulation of bone mineralization by parathyroid hormone]. | 2004 | Clin Calcium | pmid:15577058 |
| Ogata H et al. | [Prophylaxis and treatment of adynamic bone]. | 2004 | Clin Calcium | pmid:15577107 |
| Itonaga I et al. | Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. | 2004 | Bone | pmid:14751563 |
| Pan B et al. | The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). | 2004 | J. Bone Miner. Res. | pmid:14753746 |
| Valverde P et al. | Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. | 2004 | J. Bone Miner. Res. | pmid:14753747 |
| Buzi F et al. | Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14678293 |
| Cheng X et al. | Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. | 2004 | J. Biol. Chem. | pmid:14679212 |